News und Analysen
Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the
Antibe Therapeutics Recognized as a TSX Venture 50 Company for Second Consecutive Year
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it
Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
Lysogene Reports its Cash Position as of 31 December 2019
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares
Regulatory News:
Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) (Paris:ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
Palatin: Aktie fällt – wer greift nach dem Sex-Pen?
Im vergangenen Jahr feierten SD-Leser bis zu +600% Kursgewinn mit der Aktie von Palatin Technologies (WKN: A1C538). Wir rieten rechtzeitig zum Ausstieg, bevor der Kurs wieder stark nachgab. Doch
Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
VALBIOTIS meldet weltweite strategische Partnerschaft mit NESTLÉ HEALTH SCIENCE bei der Entwicklung und Vermarktung von TOTUM-63, ein pflanzlicher Wirkstoff mit klinisch nachgewiesenem Nutzen für die Stoffwechselgesundheit bei Prädiabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
VALBIOTIS Announces a Global Strategic Partnership With NESTLÉ HEALTH SCIENCE For the Development and Commercialization of TOTUM-63, a Plant-derived Active Substance With Clinically Demonstrated Metabolic Health Benefits on Prediabetics
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible ), a Research & Development company committed to scientific innovation for preventing and combating metabolic
Sensorion to Attend and Present at LSX World Congress 2020
Regulatory News:
Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and
Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
Lysogene Announces Its Corporate Agenda For 2020
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS) today announced its corporate agenda* for 2020:
17 February 2020:
Sales and cash position at the end of 2019
20 March
Cidara: NBC kassiert +136% plus Bonus!
Der No Brainer Club empfahl die Aktie von Cidara Therapeutics (WKN: A14R2R) am 26. September letzten Jahres „stark zu kaufen“. Seitdem steht ein zwischenzeitlicher Kursgewinn von +134% zu Buche
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring
Novus Therapeutics Provides Update on OP0201
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the
Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke
Aktien von Cidara Therapeutics (WKN: A14R2R) und Otonomy (WKN: A119VZ) gehörten vergangene Woche mal wieder zu den Gewinnern im Biotech-Sektor. Stehen hier ähnliche Entwicklungen an wie jüngst bei
Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 Trial for SENS-401 in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent
Sensorion Announces €5.6m Non-Dilutive Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss; French Ministry of Armed Forces to Participate in the Study
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
Transgene and BioInvent Announce Compelling Preclinical Data For BT-001 in Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (OMXS: BINV), a biotech